(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Portugal among EU countries with the most people working close to 50 hours a week - 2A Couple of Reasonable Guitars for 2024
- 3NASA says Maven spacecraft that was orbiting Mars has gone silent
- 4Exploring the Gig Economy: Examples from Consultants
- 5Israel reports second missile fire from Yemen since start of Iran war
- Data centers in space: Will 2027 really be the year AI goes to orbit?
- An Investigate of 6 Creative Specialty Mixed drinks
- Vote In favor of Your Favored Kind Of Bites
- 2 ways you can conserve the water used to make your food
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
- Finding Your Motivation: Moves toward a Satisfying Life
- EU Council president: Ukraine should receive binding guarantees
- Bayer sues COVID vaccine makers over mRNA technology
- The Green Transformation: 5 Feasible Living Practices
